Valuation: Jasper Therapeutics, Inc.

Market Cap 12.72M 11.17M 10.28M 9.58M 18.07M 1.21B 18.44M 124M 47.92M 594M 47.78M 46.74M 2.07B P/E 2026 *
-0.48x
P/E 2027 * -0.35x
Enterprise Value -270M -237M -218M -203M -383M -25.64B -391M -2.62B -1.02B -12.58B -1.01B -991M -43.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day+7.96%
1 week-7.36%
Current month+7.96%
1 month-14.92%
3 months-43.19%
6 months-75.16%
Current year-75.16%
1 week 0.32
Extreme 0.3151
0.47
1 month 0.32
Extreme 0.3151
0.64
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
7.19
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 2026-01-05
Director of Finance/CFO 54 2023-09-21
Chief Tech/Sci/R&D Officer - 2019-12-31
Director TitleAgeSince
Director/Board Member 54 2026-01-05
Director/Board Member 70 2021-09-03
Director/Board Member 58 2021-09-23
Date Insider Type Main position Quantity % Market Cap.
02-05Free

Chief Executive Officer

500,000 1.7867%
01-01Free

Chief Executive Officer

90,000 0.3216%
01-01Free

Chief Financial Officer

90,000 0.3216%
Change 5-day change 1-year change 3-year change Capi.($)
+7.96%-7.36%-92.08%-96.68% 12.72M
+1.81%+3.15%+72.38%+130.80% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.29%+7.92%+39.26%-6.25% 18.14B
+1.22%+5.51%+36.93%-30.23% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.52%+13.57%+42.43% - 12.97B
Average +2.40%+5.51%+37.16%+113.29% 23.59B
Weighted average by Cap. +1.44%+6.60%+56.12%+131.82%

Financials

2026 *2027 *
Net sales - -
Net income -36.99M -32.48M -29.89M -27.86M -52.53M -3.52B -53.6M -360M -139M -1.73B -139M -136M -6.01B -64.38M -56.52M -52.03M -48.48M -91.43M -6.12B -93.29M -626M -242M -3B -242M -236M -10.46B
Net Debt -282M -248M -228M -213M -401M -26.85B -409M -2.74B -1.06B -13.18B -1.06B -1.04B -45.86B -555M -487M -448M -418M -788M -52.73B -804M -5.39B -2.09B -25.88B -2.08B -2.04B -90.08B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Employees
22
Date Price Change Volume
26-07-01 US$0.4545 +7.96% 342,172
26-06-30 US$0.4210 +0.29% 266,512
26-06-29 US$0.4198 +23.11% 974,759
26-06-26 US$0.3410 -22.99% 1,353,034
26-06-25 US$0.4428 -9.74% 319,885
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.4545USD
Average target price
8.625USD
Spread / Average Target
+1,797.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock